Cargando…
Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
ARAMIS is an international Phase III trial demonstrating the beneficial role of darolutamide, a novel anti-androgen that has been found to prolong metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer. Darolutamide is a novel nonsteroidal androgen receptor antagonis...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958984/ https://www.ncbi.nlm.nih.gov/pubmed/31249268 http://dx.doi.org/10.4103/aja.aja_52_19 |